Compass Therapeutics (CMPX) Competitors $2.78 -0.13 (-4.47%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.90 +0.12 (+4.28%) As of 05:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. SPRY, TARS, ADPT, SDGR, JANX, ABCL, EVO, EWTX, ANIP, and NTLAShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include ARS Pharmaceuticals (SPRY), Tarsus Pharmaceuticals (TARS), Adaptive Biotechnologies (ADPT), Schrodinger (SDGR), Janux Therapeutics (JANX), AbCellera Biologics (ABCL), Evotec (EVO), Edgewise Therapeutics (EWTX), ANI Pharmaceuticals (ANIP), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Its Competitors ARS Pharmaceuticals Tarsus Pharmaceuticals Adaptive Biotechnologies Schrodinger Janux Therapeutics AbCellera Biologics Evotec Edgewise Therapeutics ANI Pharmaceuticals Intellia Therapeutics ARS Pharmaceuticals (NASDAQ:SPRY) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation. Which has higher valuation & earnings, SPRY or CMPX? ARS Pharmaceuticals has higher revenue and earnings than Compass Therapeutics. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$97.12M17.85$8M-$0.16-110.31Compass Therapeutics$850K452.27-$49.38M-$0.41-6.78 Does the media favor SPRY or CMPX? In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 4 mentions for Compass Therapeutics. ARS Pharmaceuticals' average media sentiment score of 1.23 beat Compass Therapeutics' score of 0.20 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, SPRY or CMPX? ARS Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Do insiders & institutionals have more ownership in SPRY or CMPX? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is SPRY or CMPX more profitable? Compass Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -16.11%. ARS Pharmaceuticals' return on equity of -6.94% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-16.11% -6.94% -5.60% Compass Therapeutics N/A -42.47%-38.31% Do analysts prefer SPRY or CMPX? ARS Pharmaceuticals currently has a consensus price target of $31.00, indicating a potential upside of 75.64%. Compass Therapeutics has a consensus price target of $12.67, indicating a potential upside of 355.64%. Given Compass Therapeutics' higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 SummaryARS Pharmaceuticals beats Compass Therapeutics on 9 of the 16 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$402.40M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-6.7817.9729.8525.14Price / Sales452.27262.52422.3397.16Price / CashN/A41.8335.9458.58Price / Book3.057.238.125.59Net Income-$49.38M-$54.43M$3.26B$265.48M7 Day Performance-5.76%0.22%0.68%1.22%1 Month Performance4.91%5.59%2.46%0.39%1 Year Performance175.25%9.98%27.99%23.47% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics2.9089 of 5 stars$2.78-4.5%$12.67+355.6%+208.9%$402.40M$850K-6.7820News CoverageUpcoming EarningsSPRYARS Pharmaceuticals3.4002 of 5 stars$18.35+2.7%$31.00+68.9%+84.5%$1.76B$89.15M0.0090Positive NewsUpcoming EarningsTARSTarsus Pharmaceuticals2.5483 of 5 stars$41.75+0.6%$66.67+59.7%+111.3%$1.74B$182.95M-15.2950News CoverageEarnings ReportGap UpADPTAdaptive Biotechnologies2.9894 of 5 stars$10.61-1.3%$10.57-0.4%+199.3%$1.63B$178.96M0.00790Trending NewsEarnings ReportAnalyst ForecastSDGRSchrodinger2.2946 of 5 stars$22.39+0.7%$32.75+46.3%+7.3%$1.63B$207.54M0.00790Earnings ReportGap UpJANXJanux Therapeutics2.2858 of 5 stars$25.55-1.6%$91.89+259.6%-36.0%$1.54B$10.59M-18.7930Earnings ReportABCLAbCellera Biologics2.5985 of 5 stars$4.92-3.7%$8.75+77.8%+61.2%$1.52B$28.83M-8.79500News CoverageEarnings ReportEVOEvotec1.9764 of 5 stars$4.26flat$5.93+39.3%+26.1%$1.51B$862.40M0.004,827Upcoming EarningsGap UpEWTXEdgewise Therapeutics2.1811 of 5 stars$14.26+1.0%$40.00+180.5%-18.5%$1.49BN/A-9.2060News CoveragePositive NewsEarnings ReportANIPANI Pharmaceuticals3.6738 of 5 stars$66.50-1.5%$78.88+18.6%+21.0%$1.46B$614.38M-52.36600NTLAIntellia Therapeutics4.2316 of 5 stars$13.11-3.6%$33.37+154.5%-46.2%$1.41B$57.88M-2.51600News CoverageEarnings Report Related Companies and Tools Related Companies SPRY Alternatives TARS Alternatives ADPT Alternatives SDGR Alternatives JANX Alternatives ABCL Alternatives EVO Alternatives EWTX Alternatives ANIP Alternatives NTLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPX Stock Alerts